Home Newsfeeds Rain Therapeutics Q3 EPS $(0.68), Inline

Rain Therapeutics Q3 EPS $(0.68), Inline

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

News

Why Intuitive Machines Stock Is Getting Hammered

By Henry Khederian

January 11, 12:43 PM

Intuitive Machines, Inc. (NASDAQ:LUNR) shares are trading lower by 18.2% to $2.32 Thursday morning after the company announced…

LUNR

Piper Sandler Maintains Overweight on AvidXchange Holdings, Raises Price Target to $12

By Benzinga Newsdesk

August 4, 4:42 AM

Piper Sandler analyst Brent Bracelin maintains AvidXchange Holdings (NASDAQ:AVDX) with a Overweight and raises the price target from $11 to $12.

AVDX

Clinical Advancements In Kura Oncology’s Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst

By Vandana Singh

December 22, 1:50 PM

Mizuho initiated coverage on Kura Oncology Inc (NASDAQ: KURA), spotlighting the potential of ziftomenib as a first-in-class treatment for relapsed/refractory (r/r) NPM1-m acute myeloid leukemia (AML).

KURA

Copart Late Wednesday Reports Q1 EPS $0.51 Misses $0.56 Estimate, Sales $893.37M Miss $898.80M Estimate

By Benzinga Newsdesk

November 17, 1:51 AM

Copart (NASDAQ:CPRT) reported quarterly earnings of $0.51 per share which missed the analyst consensus estimate of $0.56 by 8.93 percent. This is a 52.34 percent decrease over earnings of $1.07 per share from the same

CPRT

Rain Therapeutics Q3 EPS $(0.68), Inline

Related Posts

Why Intuitive Machines Stock Is Getting Hammered

Piper Sandler Maintains Overweight on AvidXchange Holdings, Raises Price Target to $12

Clinical Advancements In Kura Oncology’s Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst

Copart Late Wednesday Reports Q1 EPS $0.51 Misses $0.56 Estimate, Sales $893.37M Miss $898.80M Estimate